OncoSec Initiates Multiple Phase II Trials

The company announces the rollout of three Phase II clinical trials to assess its cancer-destroying, tissue-sparing electro immunotherapy technology in patients with melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma.

All three of the Phase II clinical trials are open-label, multi-center trials. They are guided and evaluated by nine senior and respected oncology researchers who provide counsel as part of the company’s scientific advisory panel for its electro immunotherapy clinical program.